Pharmexa A/S, a Danish company that is developing immunotherapy vaccines for treatment of serious cancers, is reducing its development programmes, cutting staff numbers by 20% and moving to smaller premises in an effort to conserve cash while it looks for a buyer for all or part of its assets.
